Sites of metastases before systemic treatment influence progression patterns and survival in stage IV melanoma patients
Baseline metastatic sites, treatment modality, and resistance type modulate progression patterns and survival in melanoma patients treated with first-line ICI or BRAF/MEKi.
Authors
- Alexander Maxwell Menzies (ORCID: https://orcid.org/0000-0001-5183-7562)
- I A Vergara
- Jordan W. Conway (ORCID: https://orcid.org/0000-0003-1161-9119)
- Serigne Lo (ORCID: https://orcid.org/0000-0001-5092-5544)
- Inês Pires da Silva (ORCID: https://orcid.org/0000-0003-3540-8906)
- Isabel Li (ORCID: https://orcid.org/0009-0002-0039-7274)
- Georgina Venetia Long (ORCID: https://orcid.org/0000-0001-8894-3545)
- Matteo Salvatore Carlino (ORCID: https://orcid.org/0000-0002-7861-4104)
- Richard A. Scolyer (ORCID: https://orcid.org/0000-0002-8991-0013)
- Xu Fu (ORCID: https://orcid.org/0009-0009-8200-3072)
Institutions
- The University of Sydney (AU)
- Royal Prince Alfred Hospital (AU)
- Royal North Shore Hospital (AU)
- Blacktown & Mount Druitt Hospital (AU)
- Westmead Hospital (AU)
- Melanoma Institute Australia (AU)
Publication Details
- Journal
- Immuno-Oncology Technology
- Published
- 2025-10-15
- DOI
- https://doi.org/10.1016/j.iotech.2025.101078
- Primary Topic
- Cutaneous Melanoma Detection and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00